CELUW Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Celularity Inc. - Mentions: CELU

Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease

3 months ago - By: Celularity, Inc. - Mentions: CELU

Celularity Receives Nasdaq Notice Regarding Form 10-Q

4 months ago - By: Celularity, Inc. - Mentions: CELU

Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

4 months ago - By: Celularity, Inc. - Mentions: CELU

Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies

5 months ago - By: Celularity, Inc. - Mentions: CELU

Celularity Announces Chief Financial Officer Transition

6 months ago - By: Celularity Inc. - Mentions: CELU

Celularity Receives Nasdaq Notice Regarding Form 10-Q

6 months ago - By: Celularity Inc. - Mentions: CELU

Celularity Announces Full Year 2024 Operating and Financial Results

7 months ago - By: Celularity Inc. - Mentions: CELU

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

a year ago - By: Celularity Inc. - Mentions: CELU

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

7 months ago - By: Celularity Inc. - Mentions: CELU

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

9 months ago - By: Celularity Inc. - Mentions: CELU

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

a year ago - By: Celularity Inc. - Mentions: CELU

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

a year ago - By: Celularity Inc. - Mentions: CELU

Celularity Inc. Announces Receipt of Nasdaq Notification

a year ago - By: Celularity Inc. - Mentions: CELU

Celularity’s Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

a year ago - By: Celularity Inc. - Mentions: CELU

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

a year ago - By: Celularity Inc. - Mentions: CELU

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

a year ago - By: Celularity Inc. - Mentions: CELU

Celularity Provides Corporate Update

a year ago - By: Celularity Inc. - Mentions: CELU

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

a year ago - By: Celularity Inc. - Mentions: CELU

Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference

a year ago - By: Celularity Inc. - Mentions: CELU

Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million

a year ago - By: Celularity Inc. - Mentions: CELU

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

a year ago - By: Celularity Inc. - Mentions: CELU

Celularity Appoints Richard J. Berman to its Board of Directors

a year ago - By: Celularity Inc. - Mentions: CELU

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

a year ago - By: Celularity Inc. - Mentions: CELU

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

a year ago - By: Celularity Inc. - Mentions: CELU

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

2 years ago - By: Celularity Inc. - Mentions: CELU

Celularity Inc. to Host Investor and Analyst Research & Development Day

2 years ago - By: Celularity Inc. - Mentions: CELU

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

2 years ago - By: Celularity Inc. - Mentions: CELU

Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit

a year ago - By: Celularity Inc. - Mentions: CELU

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

a year ago - By: Celularity Inc. - Mentions: CELU

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

1 years ago - By: Celularity Inc. - Mentions: CELU

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

2 years ago - By: Celularity Inc. - Mentions: CELU

Celularity Inc. to Host Investor and Analyst Research & Development Day

2 years ago - By: Celularity Inc. - Mentions: CELU

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

2 years ago - By: Celularity Inc. - Mentions: CELU

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

2 years ago - By: Celularity Inc. - Mentions: CELU

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

2 years ago - By: Celularity Inc. - Mentions: CELU

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

2 years ago - By: Celularity Inc. - Mentions: CELU

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

2 years ago - By: Celularity Inc. - Mentions: CELU

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

2 years ago - By: Celularity, Inc. - Mentions: CELU

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

2 years ago - By: Celularity, Inc. - Mentions: CELU

GX ACQUISITION CORP -CW26 (CELUW) Stock News

CELUW Latest News, Press Relases and Analysis